Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo GalluzziCaryl and Israel Englander Institute for Precision Medicine, New York City, New York, USAIlio VitaleIstituti di Ricovero e Cura a Carattere ScientificoSarah H. WarrenNanoString Technologies, Seattle, Washington, USASandy AdjemianDepartment of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, BelgiumPatrizia AgostinisCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumAitziber Buqué MartinezDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USATimothy A. ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USAGeorge CoukosUniversity of LausanneSandra DemariaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York City, New York, USAÉric DeutschSIRIC SOCRATES, DHU Torino, Faculté de Medecine, Université Paris-Saclay, Kremlin-Bicêtre, FranceDobrin DraganovCalidi Biotherapeutics, San Diego, California, USARichard L. EdelsonDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut, USASilvia C. FormentiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USAJitka FučíkováSotio, Prague, Czech RepublicLucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, ItalyUdo S. GaiplUniversitätsklinikum Erlangen, Erlangen, GermanySofia R. GameiroLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USAAbhishek D. GargCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumEncouse B. GoldenDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USAJian HaniRepertoire, Inc, Huntsville, Alabama, USAKevin J. HarringtonThe Royal Marsden Hospital/Institute of Cancer Research National Institute for Health Biomedical Research Centre, London, UKAkseli HemminkiComprehensive Cancer Center, Helsinki University Hospital, Helsinki, FinlandJames W. HodgeLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USADewan Md Sakib HossainMerck & Co. Inc, Kenilworth, New Jersey, USATim IllidgeUniversity of Manchester, NIHR Manchester Biomedical Research Centre, Christie Hospital, Manchester, UKMichael KarinDepartment of Pharmacology and Pathology, University of California at San Diego (UCSD) School of Medicine, La Jolla, California, USAHoward L. KaufmanDivision of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USAOliver KeppMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, FranceGuido KroemerUniversité de Paris, Paris, FranceJuan José LasarteProgram of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, SpainSherene LoiDivision of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaMichael T. LotzeDepartment of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USAGwenola ManicCandiolo Cancer Institute, FPO - IRCCS, Candiolo, ItalyTaha MerghoubParker Institute for Cancer Immunotherapy, MSKCC, New York City, New York, USAAlan MelcherThe Institute of Cancer Research, London, UKKaren MossmanMcMaster University, Hamilton, Ontario, CanadaFelipe PrósperHematology and Cell Therapy, Clinica Universidad de Navarra, Pamplona, SpainØystein RekdalLytix Biopharma, Oslo, NorwayMaría RescignoHumanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, ItalyChiara RigantiDepartment of Oncology, University of Torino, Torino, ItalyAntonella SistiguUOSD Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, ItalyMark J. SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, AustraliaRadek ŠpíšekSotio, Prague, Czech RepublicJohn StaggCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Quebec City, CanadaBryan E. StraussInstituto do Câncer do Estado de São PauloDaolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USAKazuki TatsunoDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut, USAStefaan Van GoolImmun-Onkologisches Zentrum Köln, Cologne, GermanyPeter VandenabeeleDepartment of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, BelgiumTakahiro YamazakiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USADmitriy ZamarinDepartment of Medicine, Weill Cornell Medical College, New York City, New York, USALaurence ZitvogelGustave Roussy Comprehensive Cancer Institute, Villejuif, FranceAlessandra CesanoESSA Pharmaceuticals, South San Francisco, California, USAFrancesco M. MarincolaRefuge Biotechnologies, Menlo Park, California, USA
2020en
Ochiq kirishOltin
Litsenziya: cc-by
ABI
Annotatsiya
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba